What are Mission Vision & Core Values of Servier Company?

How does Servier balance scientific independence with global growth?

Servier is the second-largest French pharma group, governed as a non-profit foundation that prioritizes long-term therapeutic breakthroughs over short-term market pressures. Its structure ties strategic choices to patient outcomes and scientific rigor.

By mid-2025 Servier leads in cardiology and rapidly expands in oncology, allocating its €5.3 billion turnover toward high-risk, high-reward research and global market entry while remaining mission-driven.

What are Mission, Vision & Core Values of Servier Company? Read an analysis: Servier Porter's Five Forces Analysis

Servier’s mission focuses on innovation and patient-centric therapies for cardiology, oncology and neuroscience, reaching over 150 countries and reinvesting 20% of revenue into R&D—> €1.1 billion reinvested in 2025.

Patient centricity

Prioritizes treatments that deliver meaningful clinical benefit and improve outcomes.

Innovation-driven R&D

Over €1.1 billion invested in 2025 to fund first-in-class molecules and digital health programs.

Global reach

Active in more than 150 countries, targeting unmet medical needs worldwide.

Foundation model

Non-profit governance enables reinvestment of >20% revenue into research and corporate purpose initiatives.

Therapeutic focus

Concentrates on cardiology, oncology and neuroscience to deliver high-impact therapies.

Digital patient support

Combines pharmacological treatments with digital programs to improve adherence and outcomes.

Servier’s mission emphasizes therapeutic progress, patient centricity and innovation, exemplified by the global launch of Vorasidenib for IDH-mutant glioma and digital health initiatives; see Revenue Streams & Business Model of Servier for related context.

Founded to serve health, our vision is to lead in oncology and be a partner for life in cardiology and metabolism, targeting oncology to reach 50% of group revenue by 2030; oncology revenue exceeded €1.2 billion in 2025 with 35 clinical projects.

Oncology leadership

Ambition to dominate niche and hard-to-treat cancers, focusing on GI and hematology.

Revenue target

Goal for oncology to represent 50% of group revenue by 2030; oncology > €1.2B in 2025.

R&D expansion

Strengthening R&D at Paris-Saclay and advancing a pipeline of 35 clinical projects.

Patient centricity

Positioning as a partner for life emphasizes long-term patient support and outcomes.

Strategic direction

Pivot from legacy cardiology/metabolism strengths toward high-growth oncology markets.

Ethical and corporate values

Corporate values emphasize patient commitment, scientific rigor, and long-term governance.

Founded to serve health, our vision is to lead in oncology and be a partner for life in cardiology and metabolism, targeting oncology to reach 50% of group revenue by 2030; oncology revenue exceeded €1.2 billion in 2025 with 35 clinical projects.

For details on Servier mission statement, Servier vision and Servier core values see Mission, Vision & Core Values of Servier

Servier’s core values guide its patient-focused research, collaborative culture, and long-term strategic choices. These shared principles shape daily decisions and the company’s approach to innovation, quality and societal impact.

Care

Servier places patients and employees at the center of actions, involving patient advocates in trial design and driving CSR efforts to cut manufacturing carbon emissions by 25% by 2025.

Dare to innovate

Intellectual curiosity and investment in new modalities underpin R&D, with the group allocating 21.5% of turnover to research, supporting cell, gene and RNA technologies.

Grow together

Collaboration and collective intelligence drive partnerships—over 70 active collaborations with academia and biotech—to accelerate discovery and translate lab insights into strategy.

Commit to succeed

Focus on quality and delivery is reflected in manufacturing: 98% of medicines produced in-house across 16 global sites to ensure supply reliability.

Explore how Servier’s mission and vision shape its strategic direction and operational choices next; read Brief History of Servier to connect values with past decisions.

Values — Servier identifies four core values: Care; Dare to innovate (R&D spend 21.5% of turnover); Grow together (70+ partnerships); Commit to succeed (98% in‑house production, 16 sites).

Mission and vision statements steer strategic choices, resource allocation and R&D priorities across the organization. They shape market entries, M&A activity and daily management through clear long-term objectives.

Mission, Vision & Strategic Role

The mission anchors patient-centric research and access; the vision sets the ambition to lead in key therapeutic areas, notably oncology and rare diseases.

• The mission focuses on improving patient outcomes through innovation and accessible therapies
• The vision targets global leadership in oncology and specialty care by 2030
• 56% of group revenue generated outside the EU supports global expansion goals
• Financial discipline and reinvestment guided by a foundation model prioritize long-term R&D

Strategic Direction

Vision-driven choices redirected the geographic and therapeutic footprint, emphasizing high-growth markets and oncology leadership.

Major Acquisition

The USD 2.25 billion acquisition of Agios' oncology business was guided by the goal to secure a U.S. oncology foothold aligned with the vision.

Revenue & Market Impact

Expansions and new subsidiaries in growth regions contributed to the 56% revenue share outside the EU and rising oncology sales.

Performance Metrics

Oncology sales grew 15% year-over-year; over 50% of pipeline candidates are positioned as potential first-in-class assets.

Operational Alignment

The Servier Leadership Way evaluates managers on value alignment, tying day-to-day decisions to mission and vision outcomes.

Governance & Purpose

The foundation ownership model directs profits to R&D reinvestment; CEO Olivier Laureau frames this as a responsibility to optimize every Euro for patients.

Read how these strategic pillars drive concrete improvements in the next chapter: Core Improvements to Company's Mission and Vision. Owners & Shareholders of Servier

Four targeted improvements can modernize Servier's mission, vision and core values to reflect the 2025 pharma landscape. These refinements emphasize digital intelligence, sustainability, measurable impact and stakeholder collaboration to strengthen Servier's corporate purpose and strategic direction.

Embed Digital Intelligence into the Vision

Refine Servier vision to explicitly include AI and data-driven therapies, positioning the company as a leader in integrating digital diagnostics with drug development to improve outcomes and accelerate time-to-market.

Quantify Patient-Centric Impact

Add measurable patient-outcome targets to the Servier mission statement, such as reducing disease-specific morbidity by defined percentages within set timeframes to demonstrate accountability and impact.

Elevate Sustainability in Corporate Values

Integrate a clear commitment to sustainable therapeutics and green procurement into Servier core values, with public targets for reducing carbon intensity and pharmaceutical waste across operations by 2030.

Strengthen Collaborative R&D and Open Innovation

Formalize partnerships and data-sharing principles in the Servier corporate values to accelerate translational research, aiming to increase external collaborations by 30% and shorten development timelines.

Improvements While Servier’s mission and vision are robust, there are areas where they could be refined to better reflect the 2025 pharmaceutical landscape. Currently, the vision focuses heavily on therapeutic areas but could be strengthened by explicitly incorporating digital transformation and artificial intelligence. Competitors are increasingly framing their visions around 'Data-Driven Health,' and Servier could benefit from a refinement such as 'Leading the integration of digital intelligence with therapeutic excellence.' This would better align with the evolving industry trend where software-as-a-medical-device and AI-driven diagnostics are becoming inseparable from drug therapy.

Another growth opportunity lies in making environmental sustainability a more visible part of the core mission. As global healthcare systems increasingly prioritize 'Green Procurement,' adding a commitment to 'Sustainable Therapeutic Progress' would resonate more strongly with modern healthcare payers and academic partners. These refinements would not change the company’s soul but would modernize its external messaging to reflect the 2025 reality of a more interconnected, digital, and environmentally conscious healthcare ecosystem.

Keywords included: Servier mission statement; Servier vision; Servier core values; Servier company purpose; Servier corporate values; Servier strategic direction; What is the mission of Servier Pharmaceuticals; Servier company core beliefs and principles; Detailed explanation of Servier vision and values; Servier corporate purpose and objectives; How to find Servier core values documentation; Servier company culture based on values; Servier mission vision and values for employees; Servier commitment to patients and healthcare; Servier ethical guidelines and values; Servier long term goals and vision statement; Servier patient centricity values; Servier research and development mission; Servier corporate social responsibility values; What are the foundational values of Servier; Servier governance and core values explained.

For context and competitive positioning see Competitors Landscape of Servier.